ON DEMAND WEBINAR
Monday, September 11 | 2pm ET
Duration: 1 hour
Can't make the live date? Register and we'll send you a link to the recording. ​

Biosimilar drugs stand to save $181 billion in U.S. prescription costs between 2013 and 2028.^[1] Fueling that growth is their attractive pricing, with some discounts as high as 85 percent ^[1] or more compared to reference products, while providing highly similar quality, efficacy, and safety.

But with just 41 biosimilars currently approved for 11 reference biologics, there’s more potential for further development. Given the opportunities, what should providers, pharmacists, and healthcare leaders understand about the pricing trends now and in the future? 

Join experts from The Biosimilars Forum, Pontchartrain Cancer Center, and Samsung Bioepis as they discuss:

• Updates surrounding FDA approvals and launch status for U.S. biosimilars
• Biosimilar pricing within WAC, ASP, and NADAC perspectives and their trends across therapeutic areas
• Biosimilar utilization patterns by each therapeutic area and future predictions
• Context and implications of the FDA’s interchangeability designation

SPEAKERS

Tom Newcomer
Vice President and Head of US Market Access
Samsung Bioepis

Julianna (Julie) Reed
Executive Director
Biosimilars Forum

Kathy Oubre
CEO
Pontchartrain Cancer Center